![]() |
市場調查報告書
商品編碼
1495997
全球酵素結合免疫吸附檢測法(ELISA) 市場 - 2024 年至 2029 年預測Global Enzyme-Linked Immunosorbent Assay (ELISA) Market - Forecasts from 2024 to 2029 |
酵素結合免疫吸附檢測法(ELISA) 市場預計將以 5.56% 的複合年成長率成長,從 2022 年的 21.38 億美元增至 2029 年的 31.23 億美元。
ELISA(酵素結合免疫吸附檢測法)或酵素免疫分析法測定(EIA)是一種基於板的測量技術,旨在檢測和定量勝胜肽、蛋白質、抗體和荷爾蒙等物質。 ELISA 通常用作更詳細測試之前的篩檢工具。由於 ELISA 反應物固定在微孔盤表面,因此在測定過程中可以輕鬆分離結合和未結合的物質。這使其成為測定粗製劑中特定分析物的強大工具。
ELISA 的常見診斷用途包括 HIV 感染、懷孕檢測和蛋白質檢測。預計 ELISA 市場在預測期內將穩定成長。這種成長可能是由於感染疾病和慢性病患病率的上升以及對 ELISA 作為具有成本效益的診斷工具的需求。然而,有關 ELISA 的嚴格監管要求和不利的報銷政策可能會阻礙預測期內的市場成長。
推動市場擴張的關鍵因素之一是愛滋病毒、肝炎、瘧疾、登革熱和流感等感染疾病率的上升。世界衛生組織估計,到 2021年終,全球有 3,840 萬名愛滋病毒感染者,其中三分之二以上居住在非洲。世界衛生組織也聲稱,登革熱是世界面臨的十大健康威脅之一。過去 50 年來,全球登革熱發生率增加了約 3,000%。世界衛生組織也估計,2019 年全球有超過 2.96 億人感染B型肝炎。
由於感染疾病發生率不斷增加,對診斷的需求預計也會增加。由於擴大使用尖端診斷技術(例如酵素結合免疫吸附測試)來篩檢這些疾病,預計該市場將會擴大。
此外,全球越來越多的老年人患有感染疾病和慢性病的高風險並需要常規診斷,預計將刺激市場擴張。根據 NCBI(美國生物技術資訊中心)於 2021 年發布的消息,與年輕人相比,老年患者更有可能發生潛在危險的疾病。因此,這些因素預計將增加對酵素結合免疫吸附檢測法的需求,從而顯著提高市場成長。
擴大使用酵素結合免疫吸附測定測試來診斷特定抗原,預計將佔據疾病診斷市場的重要佔有率。世界衛生組織估計,到 2022 年,非傳染性疾病每年將導致約 4,100 萬人死亡,佔全球死亡人數的 71%。此類疾病的發生增加了對有效診斷技術(例如用於快速檢測的 ELISA)的需求,以最大限度地降低死亡率。
此外,根據全球癌症觀察站的數據,2020年將有約1,930萬人新診斷出癌症,約1,000萬人將死於癌症。由於 ELISA 是評估抗原的有用工具,全球癌症發生率的上升正在推動其需求。
根據 Nature Scientific 2020 年的一項研究,酵素結合免疫吸附檢測法可用於尋找乳腺癌和前列腺癌抗原。這種準確的抗原篩檢和具有成本效益的診斷預計將在分析期間增加 ELISA 需求並推動市場擴張。
預計北美將佔據很大的市場佔有率
由於ELISA等篩檢設備技術突破的市場開拓迅速,美國很可能主導全球市場。該地區多種感染疾病和慢性疾病的發生率不斷增加,增加了對酵素酵素結合免疫吸附檢測法的需求。例如,美國疾病管制與預防中心 (CDC) 報告稱,到 2022 年,超過 60% 的美國人將患有至少一種慢性疾病,例如癌症、心血管疾病或中風。
由於研發支出的增加和診斷資金的大量投入,預計該地區的市場將會成長。根據 Binder Dijker Otte USA 2020 年報告,生技指數中的上市公司 2020 年研發支出平均成長約 16% 至 2.8425 億美元。
此外,2021 年,美國衛生與公眾服務部宣布從美國救援計畫中撥款 6.5 億美元,用於提高快速、高品質診斷測試的生產能力。因此,所有這些方面預計將在預測期內很好地支持北美區域市場。
The global Enzyme-Linked Immunosorbent Assay (ELISA) market is projected to grow at a CAGR of 5.56% increasing from US$2.138 billion in 2022 to US$3.123 billion in 2029.
ELISA (enzyme-linked immunosorbent assay) or enzyme immunoassay (EIA) is a plate-based assay technique designed for detecting and quantifying substances such as peptides, proteins, antibodies, and hormones. ELISA is often used as a screening tool before further in-depth tests are ordered. Reactants of the ELISA are immobilized to the microplate surface, making it easy to separate bound from non-bound material during the assay. This makes it a powerful tool for measuring specific analytes within a crude preparation.
The common diagnostic applications of ELISA are HIV infection, pregnancy tests, detection of proteins, etc. The ELISA market is expected to show robust growth during the forecast period. The growth may be attributed to the rising incidence of infectious and chronic diseases, which require ELISA as a cost-effective diagnostic tool. However, stringent regulatory requirements, as well as unfavorable reimbursement policies about ELISA, might hamper the market growth during the given time frame.
One of the key drivers fuelling the market's expansion is the rising prevalence of infectious diseases like HIV, Hepatitis, malaria, dengue, and influenza, among other ailments. At the end of 2021, the WHO estimated that there were 38.4 million HIV-positive individuals worldwide, with more than two-thirds of them living in Africa. The WHO also claimed that dengue fever was among the top ten health threats facing the world. Over the past 50 years, dengue incidences have increased by about 3000% worldwide. WHO also estimated that more than 296 million individuals worldwide have hepatitis B infection as of 2019.
The demand for diagnosis is anticipated to rise as a result of the rising occurrence of infectious diseases. The market is anticipated to expand due to the rising use of cutting-edge diagnostic techniques for screening these disorders, such as enzyme-linked immunosorbent tests.
Additionally, the growing geriatric population, which is globally at risk of contracting illnesses and chronic diseases and requires routine diagnosis, is anticipated to fuel market expansion. In comparison to younger individuals, potentially dangerous illnesses are more likely in elderly patients, according to the NCBI (National Center for Biotechnology Information), which published this information in 2021. Thus, it is anticipated that these factors will considerably raise the market's growth by boosting demand for enzyme-linked immunosorbent assays.
Due to the growing use of enzyme-linked immunosorbent assay tests for the diagnosis of specific antigens, a sizable share of the disease diagnosis market has been predicted. In 2022, the WHO estimated that non-communicable illnesses caused around 41 million deaths each year, equivalent to 71% of all deaths worldwide. Due to these occurrences, there is now a greater need for efficient diagnostic techniques like ELISA for prompt detection to minimize death occurrences.
Additionally, according to the Global Cancer Observatory, there were approximately 19.3 million new cases of cancer and nearly 10.0 million cancer deaths worldwide in 2020. As ELISA is a useful instrument for assessing antigens, the rise in cancer incidence around the world is driving up demand for it.
The Enzyme-Linked Immunosorbent Assay can be used to find both breast cancer antigens and prostate cancer antigens, according to a 2020 Nature Scientific study. Such accurate antigen screening and cost-effective diagnosis are anticipated to boost ELISA demand and drive the market's expansion during the analyzed period.
North America is Expected to Hold a Significant Share in the Market
Because of the rapid development of technological breakthroughs in screening instruments like ELISA, the US is likely to dominate the global market. The increasing incidences of multiple infectious and chronic diseases in this demography are contributing to the strong demand for Enzyme-Linked Immunosorbent Assay. For instance, the CDC (Centre for Ailment Control and Prevention) reported in 2022 that over 60% of Americans had at least one chronic disease, such as cancer, cardiovascular disease, or stroke.
The market in this region is anticipated to grow as a result of rising R&D expenditures as well as numerous funding initiatives for diagnostics. Listed firms on the biotechnology index expanded their R&D spending by about 16% on average in 2020 to USD 284.25 million in the US, based on the Binder Dijker Otte USA Reports from 2020.
Additionally, in 2021, the Department of Health and Human Services said that it would deploy USD 650 million from the American rescue plan to increase production capabilities for swift, high-quality diagnostic tests. Therefore, it is projected that all of these aspects will support the North American regional market well over the predicted period.